Sun Pharma settles litigation over Linzess generic
Mumbai-based Sun Pharma has settled its litigation with Allergan and Ironwood Pharmaceuticals. The companies reached an agreement Tuesday to resolve litigation surrounding Sun’s submission of an abbreviated new drug application for a generic of Linzess (linaclotide capsules).
As part of the agreement, Allergan and Ironwood have granted Sun Pharma and its subsidiaries a license to market its generic of the treatment for irritable bowel syndrome treatment with constipation and chronic idiopathic constipation in the United States starting Feb. 1, 2031 or earlier under certain circumstances. The launch would be subject to Food and Drug Administration approval.
“Ironwood and Allergan have established Linzess as the branded prescription market leader in the IBS-C and CIC category,” Ironwood chief commercial officer Tom McCourt said. “We are pleased to have resolved this patent litigation with Sun Pharma, as we believe it confirms the strength of our Linzess intellectual property. Allergan and Ironwood are committed to continuing to grow the Linzessfranchise for many years to come.”
Pharmasave helps Canadians kick nicotine in 2018
Pharmasave’s latest effort is focusing on helping Canadians quit nicotine. The company has encouraged Canadians to understand their personal health risks from smoking and get pharmacist support to help them become tobacco-free. Despite having one of the lowest smoking rates the world, smoking tobacco remains the leading cause of preventable death in Canada.
“There is still so much that we can and should do,” Pharmasave national director of pharmacy innovation Allison Nourse said. “Becoming tobacco-free is not easy and often takes numerous attempts. Consistent support and advocacy from a qualified healthcare professional to motivate and encourage behavioral changes related to smoking habits, while at the same time managing nicotine withdrawal symptoms, can increase the success rate of becoming tobacco-free. Regardless of how long a person has been smoking or using other forms of tobacco, Pharmasave pharmacists can help people become tobacco-free, improving their quality of life and increasing positive health outcomes.”
Pharmacists can counsel patients on available options for quitting, including medication and nicotine replacement products, as well as outline a step-by-step plan that includes strategies for handling cravings and managing withdrawal symptoms, the company said. Pharmasave said that studies have shown increased effectiveness from combining counseling and medication when helping individuals quit smoking.
Fresenius Kabi launches Velcade alternative
Fresenius Kabi has introduced its alternative of Takeda Oncology’s Velcade (bortezomib for injection). The Lake Zurich, Ill.-based company said that this addition to its oncology offerings is the first available alternative for intravenous use.
Fresenius Kabi’s product is available in a single-dose vial that contains 3.5 mg of lyophilized powder.
“Fresenius Kabi bortezomib is a cost-efficient product alternative for our customers and the patients they treat,” Fresenius Kabi USA president and CEO John Ducker said. “We are proud to offer an expansive oncology portfolio and will continue to develop these essential medicines”
Fresenius Kabi’s product is indicated to treat patients with multiple myeloma and patients with mantle cell lymphoma who have received at least one prior treatment.
According to Takeda’s quarterly filings, Velcade has had U.S. sales of $60.2 million for the first two quarters of its fiscal year 2017. For the full fiscal year 2016, Takeda reported $112.9 million in U.S. sales for Velcade.